SHAREHOLDERS' EQUITY (Details)
$ / shares in Units, $ in Thousands |
|
|
|
12 Months Ended |
|
Feb. 12, 2021
USD ($)
$ / shares
shares
|
Feb. 09, 2021
USD ($)
$ / shares
shares
|
May 20, 2020
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Stock offering, shares sold (in shares) |
|
8,750,000
|
5,650,000
|
|
|
|
| Stock offering, purchase price (in dollars per share) | $ / shares |
|
$ 3.92
|
$ 2.48
|
|
|
|
| Stock offering, gross proceeds | $ |
|
$ 34,300
|
$ 14,000
|
|
|
|
| Stock offering, net proceeds | $ |
|
$ 32,200
|
$ 13,100
|
|
|
|
| Issuance of common stock in connection with Zyla Merger (in shares) |
|
|
|
6,400,000
|
|
|
| Warrants exercised (in shares) |
|
|
|
|
1,200,000
|
1,500,000
|
| Common shares issued (in shares) |
|
|
|
|
1,200,000
|
1,500,000
|
| Warrants outstanding (in shares) | $ |
|
|
|
|
$ 400
|
|
| Options exercised during period (in shares) |
|
|
|
|
72,750
|
0
|
| Proceeds from issuance of common stock | $ |
|
|
|
|
$ 44,861
|
$ 88
|
| Zyla Life Sciences |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Merger exchange ratio |
|
|
|
2.5
|
|
|
| Zyla Life Sciences | Iroko | Warrant Agreements |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Exercise aggregate ownership percentage maximum threshold |
|
|
|
49.00%
|
|
|
| Exercise aggregate ownership percentage term |
|
|
|
18 months
|
|
|
| Zyla Life Sciences | Money market funds | Zyla Life Sciences |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Purchase price, number of shares outstanding, per share (in dollars per share) | $ / shares |
|
|
|
$ 0.0016
|
|
|
| ESPP |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Exercise price of awards as percentage of the fair value of common stock (at least) |
|
|
|
|
85.00%
|
|
| Shares sold (in shares) |
|
|
|
|
3,929
|
45,682
|
| Weighted average purchase price of shares sold (in dollars per share) | $ / shares |
|
|
|
|
$ 1.40
|
$ 1.91
|
| Proceeds from shares sold | $ |
|
|
|
|
$ 0
|
$ 100
|
| Stock Options |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Proceeds from issuance of common stock | $ |
|
|
|
|
$ 200
|
|
| Common Stock |
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
| Issuance of common stock in connection with Zyla Merger (in shares) |
[1] |
|
|
|
|
6,370,000
|
| Shares sold (in shares) |
[1] |
|
|
|
4,000
|
46,000
|
| Options exercised during period (in shares) |
[1] |
|
|
|
73,000
|
|
|
|